Stock Market Reviews

Read and share opinions on RDHL (RedHill Biopharma Ltd.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement
  Nov 4, 2025
• RedHill Biopharma Receives Nasdaq Staff Determination Notification
  Oct 22, 2025
• CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
  Oct 20, 2025
• RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
  Oct 20, 2025
• RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®
  Oct 6, 2025
• RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo
  Sep 29, 2025
• RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights
  Sep 5, 2025
• RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win
  Aug 20, 2025
• RedHill Received Talicia® Licensing Payments Totaling $1.1 Million
  Aug 18, 2025
• RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease
  Jul 21, 2025
• RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer
  Jul 1, 2025
• RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win
  May 13, 2025
• RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress
  May 2, 2025
• RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107
  Apr 28, 2025
• RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
  Apr 17, 2025
• RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption
  Apr 16, 2025
• RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights
  Apr 10, 2025
• RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation
  Mar 18, 2025